Neothermia Corp. v. Rubicor Medical, Inc.

345 F. Supp. 2d 1042, 2004 U.S. Dist. LEXIS 23340, 2004 WL 2623987
CourtDistrict Court, N.D. California
DecidedNovember 15, 2004
DocketC-03-4277 VRW (EMC)
StatusPublished
Cited by6 cases

This text of 345 F. Supp. 2d 1042 (Neothermia Corp. v. Rubicor Medical, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Neothermia Corp. v. Rubicor Medical, Inc., 345 F. Supp. 2d 1042, 2004 U.S. Dist. LEXIS 23340, 2004 WL 2623987 (N.D. Cal. 2004).

Opinion

ORDER GRANTING IN PART AND DENYING IN PART DEFENDANT’S MOTION TO COMPEL AND FOR SANCTIONS; AND GRANTING IN PART AND DENYING IN PART PLAINTIFF’S MOTION TO COMPEL, FOR A PROTECTIVE ORDER, AND TO EXTEND DISCOVERY CUT-OFF (Docket Nos. 49, 53)

CHEN, United States Magistrate Judge.

In this suit, Plaintiff Neothermia Corporation asserts against Defendant Rubicor Medical, Inc. claims for patent infringement and breach of a nondisclosure agreement. Neothermia alleges that Rubicor obtained proprietary information in the course of business negotiations and used and revealed the information in Rubicor’s own patent application. Neothermia has moved to compel production of documents pertaining to Rubicor’s product involved in the alleged infringement and breach. See Docket No. 53. Rubicor has objected, relying in part on' Neothermia’s purported failure to comply with California Code of Civil Procedure § 2019(d).. Rubicor has also filed its own discovery motion regarding a deposition. See Docket No. 49. The District Court referred both discovery motions to the undersigned for resolution. Having considered the parties’ motions and accompanying submissions, as well as the parties’ joint letter of November 3, 2004 and the oral argument of counsel, the Court hereby GRANTS in part and DENIES in part each party’s motion.

I. DISCUSSION

In their joint letter of November 3, 2004, see Docket No. 62, the parties stated that they had reached agreement on eleven matters, conditioned on the Court’s resolution of whether Rubicor may withhold discovery from Neothermia pursuant to California Code of Civil Procedure § 2019(d).

A. Applicability of California Code of Civil Procedure Section 2019(d)

Section 2019(d) provides: “In any action alleging the misappropriation of a trade secret under the Uniform Trade Secrets Act [ (UTSA) ] ..., before commencing discovery relating to the trade secret, the party alleging the misappropriation shall identify the trade secret with reasonable particularity....” Cal.Code Civ.Proc. § 2019(d). Neothermia argues that the statute is not applicable to the instant case because it has asserted only a claim for breach of the nondisclosure agreement, not a claim for trade secret misappropriation pursuant to the UTSA. See Cal. Civ. Code § 3426 et seq. (UTSA).

' Although neither party has cited any case which addresses the issue question, thus presenting an issue of first impression, the Court concludes that § 2019(d) does apply to the case at bar. On its face, § 2019(d) is not limited to misappropriation claims pursuant to the UTSA. By its terms, § 2019(d) does not require that an identification of a trade secret be made in any action in which a claim for a violation of the UTSA is being asserted. Rather, it requires only that an identification of a trade secret be made “[i]n any action alleging-the misappropriation of a trade secret under the Uniform Trade Secrets Act.”

*1044 Cal.Code Civ. Proc. § 2019(d) (emphasis added). In the instant case, Neothermia’s allegation that Rubicor breached the nondisclosure agreement constitutes a “misappropriation” as that term is defined by the UTSA. California Civil Code § 3246.1(b)(2)(B)(ii) defines misappropriation as “[disclosure or use of a trade secret of another without express or implied consent by a person who ... [a]t the time of disclosure or use, knew or had reason to know that his or her knowledge of the trade secret was ... [acquired under circumstances giving rise to a duty to maintain its secrecy or limit its use.” Cal. Civ.Code § 3426.1(b)(2)(B)(ii). Section 2019(d) thus applies not only to theft of trade secrets, but also to disclosure of secrets in violation of a nondisclosure agreement as alleged in the instant case.

The Court’s conclusion is consistent not only with the text of § 2019(d) but also its purposes. As explained in Computer Economics, Inc. v. Gartner Group, Inc., 50 F.Supp.2d 980, 985 (S.D.Cal.1999), the early identification of trade secrets, as required by the statute, serves four purposes: (1) it promotes investigation of claims prior to suit and discourages the filing of meritless trade secret complaints; (2) it prevents plaintiff from using the discovery process as a means to obtain the defendant’s trade secrets; (3) it frames the appropriate scope of discovery; and (4) it enables the defendant to form complete and well-reasoned defenses. In the case at bar, where misappropriation in the form of wrongful disclosure of trade secrets is alleged, all of these considerations, particularly (3) and (4), apply.

B. Compliance with California Code of Civil Procedure Section 2019(d)

Although the Court concludes that § 2019(d) is applicable to the instant case, it also finds that, based on the parties’ joint letter (filed after the Court-ordered meet and confer), there is no real dispute that Neothermia has in fact identified its trade secrets with “reasonable particularity” as required by § 2019(d). Cal.Code Civ. Proc. § 2019(d). Neothermia has satisfied the statute by way of interrogatory responses and declarations. Rubicor’s only remaining concern is that Neothermia will continue to amend its trade secret identification (it already has once) thereby providing a shifting basis to which Rubicor must repeatedly respond. See Docket No. 62 (joint letter of 11/3/04, at 4) (“Rubicor asks this Court for an order ... that Neothermia may not ... further amend its trade secrets before Rubicor must produce more documents. Otherwise, this case could go on forever with an ever-moving target.”).

However, § 2019(d) contains no express provision that prevents a party from amending its trade secret identification thereunder. Moreover, Federal Rule of Civil Procedure 26(e) allows a party to supplement disclosures or discovery responses in certain circumstances — more specifically, it imposes a duty to supplement upon learning that the disclosures or responses are incomplete or incorrect. See Fed.R.Civ.P. 26(e) (discussing circumstances in which a party must supplement or correct discovery disclosure). To read § 2019(d) as to ban a plaintiff from amending its disclosures or responses would raise serious questions under the Erie doctrine. See Computer Economics, 50 F.Supp.2d at 986-92 (finding general application of § 2019(d) consistent with Federal Rules of Civil Procedure and applicable under Erie).

On the other hand, Neothermia should not have free rein to amend its trade secret identification without limits.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Vitec Electronics v. Veris Industries CA4/3
California Court of Appeal, 2021
Loop AI Labs Inc. v. Gatti
195 F. Supp. 3d 1107 (N.D. California, 2016)
SkinMedica, Inc. v. Histogen Inc.
869 F. Supp. 2d 1176 (S.D. California, 2012)
Perlan Therapeutics, Inc. v. Superior Court
178 Cal. App. 4th 1333 (California Court of Appeal, 2009)
Advanced Modular Sputtering, Inc. v. Superior Court
33 Cal. Rptr. 3d 901 (California Court of Appeal, 2005)

Cite This Page — Counsel Stack

Bluebook (online)
345 F. Supp. 2d 1042, 2004 U.S. Dist. LEXIS 23340, 2004 WL 2623987, Counsel Stack Legal Research, https://law.counselstack.com/opinion/neothermia-corp-v-rubicor-medical-inc-cand-2004.